Raymedica today announced that it has received FDA approval to begin enrolling patients in a US clinical study to evaluate the potential benefits of its HydraFlex Nucleus Arthroplasty System, a new non-fusion technology for the treatment of degenerative disc disease. Implanted via an Anterior lateral RetroPeritoneal Approach (ARPA), the HydraFlex device is designed to replace the diseased nucleus potentially providing pain relief and maintaining disc height. Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060629005044&newsLang=en)